Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT improves locoregional staging compared with MRI in patients undergoing surgery for intermediate and high-risk prostate cancer. PSMA ...
In a parallel randomised trial, O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET led to comparable survival outcomes to contrast-enhanced T1-weighted (CE-T1) MRI for re-irradiation planning in patients ...
A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...
Current PET/MRI imaging of healthy and damaged mouse kidneys using the dual contrast agent [18F][Gd(FL1)]. The imaging provides consistent signals from both PET and MRI. In healthy kidneys, the center ...
A single-center observational study of more than 1,000 oncological examinations has demonstrated that positron emission tomography/magnetic resonance imaging (PET/MRI) facilitates cancer staging as ...
A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...
Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results